Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basal cell carcinoma treated with interferon.

D Ikić1, I Padovan, N Pipić

  • 1Department of Medicine, Yugoslav Academy of Sciences and Arts, Zagreb.

International Journal of Dermatology
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spotlight: efficient automated global optimization in rietveld analysis of diffraction data.

Scientific reports·2025
Same author

Successful emergency Lichtenberger lateralisation for immediate bilateral laryngeal immobility after total thyroidectomy: a CARE case report.

The Journal of laryngology and otology·2023
Same author

Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-N<sup>G</sup>-nitro-L-arginine methyl ester worsening.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2022
Same author

Potential of root nodule nonrhizobial endophytic bacteria for growth promotion of Lotus corniculatus L. and Dactylis glomerata L.

Journal of applied microbiology·2021
Same author

Surface Tensions between Active Fluids and Solid Interfaces: Bare vs Dressed.

Physical review letters·2020
Same author

Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.

Journal of endocrinological investigation·2020
Same journal

SENTINOLD and the Challenge of Meaningful Risk Prediction in Melanoma.

International journal of dermatology·2026
Same journal

The "Stamp-n-Tack" Technique: An Ink-Guided Precision Method for Anchoring Tissue After Releasing Facial Retaining Ligaments in Large Facial Flap Reconstruction.

International journal of dermatology·2026
Same journal

Counterfactual Dermatology With Generative Models.

International journal of dermatology·2026
Same journal

Correlation of Clinical and Histopathological Features With Anti-Desmoglein Antibody Profile in Pemphigus Patients.

International journal of dermatology·2026
Same journal

Paracetamol-Induced Generalized Bullous Fixed Drug Eruption With Positive Anti-BP230 Antibody and Confirmed With Oral Provocation Test in a Child: A Case Report From the Philippines.

International journal of dermatology·2026
Same journal

Clinicopathological Challenge: A Painful Violaceous Reticulated Patch.

International journal of dermatology·2026
See all related articles

Human natural leukocytic interferon (HNLI) and recombinant interferon (rIFN) alpha 2c effectively treat basal cell carcinoma. Both therapies demonstrated significant positive outcomes in patients, with mild side effects observed.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Basal cell carcinoma (BCC) is a common skin cancer.
  • Interferons are cytokines with antiviral and antitumor properties.

Purpose of the Study:

  • To evaluate the efficacy of human natural leukocytic interferon (HNLI) and recombinant interferon alpha 2c (rIFN alpha 2c) in treating basal cell carcinoma.

Main Methods:

  • Seventy-two patients with basal cell carcinoma received treatment with HNLI or rIFN alpha 2c for 3-6 weeks.
  • Dosages varied, with HNLI ranging from 400,000 to 1,200,000 units and rIFN alpha 2c from 2,000,000 to 5,000,000 units.
  • Treatment outcomes were assessed via histopathologic and clinical findings.

Main Results:

  • HNLI treatment led to a cure in 52 out of 72 patients, with no cancer cells found in post-treatment biopsies.

Related Experiment Videos

  • Tumor reduction of 25%-90% was observed in nine patients treated with HNLI.
  • rIFN alpha 2c therapy resulted in a cure for five out of 12 patients, with no cancer cells detected post-treatment.
  • Tumor reduction of 25%-90% was noted in seven out of 12 patients receiving rIFN alpha 2c.

    • Conclusions:

    • Both HNLI and rIFN alpha 2c are effective therapeutic options for basal cell carcinoma.
    • The observed side effects associated with both interferon treatments were mild.